Practice Areas - Equity Capital Markets Law Firms and Lawyers
| Deal Date: | 11-07-2014 | Practice Area: | Equity Capital Markets |
| Deal Title: | Luye Pharma Group - Hong Kong Stock Exchange IPO | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Ashurst advised Luye Pharma Group on its global offering and listing on the Hong Kong Stock Exchange. The Hong Kong IPO raised approximately USD760 million, making it the largest pharmaceutical IPO globally in over three years. UBS, Citi and CLSA acted as joint global coordinators on the transaction.
Luye Pharma Group, a specialty pharmaceutical company, is engaged in the research and development, production and sale of natural drugs, new formulations and biotechnology products in Mainland China and internationally. Luye Pharma Group delisted from the Singapore Stock Exchange in 2012 through a private-equity backed privatisation transaction.
The Ashurst team was led by Hong Kong-based corporate partner Lina Lee, assisted by senior associates Tracy Li and Chin Yeoh and solicitor Sarah Lee. Partner Stuart Rubin led the Ashurst US securities team, assisted by associate Li Jiang. New York-based partner David Nirenberg and associate Amanda Goehring advised on US tax matters.
|
||
| Financial Center: | Hong Kong | Value: | 500.01-1000.00 |
| Advised Party: | Issuer | Law Firm | Ashurst |
| Issuer Jurisdiction- | China | Listing Jurisdiction- | Hong Kong |
| Classification: |
Initial Public Offerings Hong Kong Stock Exchange |
Lawyer | Lina Lee |
